Customer Service: 866-788-9007

Customer Service: 866-788-9007

Customer Service: 866-788-9007

About Us

Castle-Wave

About Us

Innovators in Diagnostic and Prognostic Tests for Dermatologic Cancers

Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Our tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information.

Our DecisionDx tests provide personalized, clinically actionable information to help healthcare providers and patients make more informed decisions about their treatment plans. Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile, or GEP, test that more accurately predicts a patient’s risk of metastasis or recurrence as well as sentinel lymph node positivity. DecisionDx®-SCC is our GEP test that predicts the risk of metastasis for patients with cutaneous squamous cell carcinoma who have one or more risk factors. DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Our comprehensive diagnostic offering leverages the strengths of myPath Melanoma and DecisionDx® DiffDx™-Melanoma.  These gene expression profile tests are designed to provide a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing difficult-to-diagnose melanocytic lesions.

We also have active research and development programs for tests in other dermatologic diseases with high clinical need.

All of our tests are performed in a CLIA-certified, CAP-accredited clinical laboratory.  Our laboratory is licensed to perform tests throughout the U.S., and proprietary genomic tests have been separately approved by the New York State Department of Health.

“Most cancer treatment plan decisions are based on the risk that a tumor will recur or metastasize. Reliance on clinical or pathology factors alone may under or over-estimate the actual risk. At Castle Biosciences, we develop innovative tests using tumor biology that can result in more accurate treatment plan decisions."

Derek Maetzold

Founder, President, and CEO

For More Information on Castle GEP Tests